Heat Biologics Inc. stock ended the trading week down 5.59 percent at 97 cents per share, the lowest since Aug. 1, when shares closed at 91 cents per share.

The Durham-based company said it’s moving into 2017 with no long-term debt after paying the remaining $2.7 million on a loan from a California bank, Pacific Western Bank, on Dec 6.

The company received $7.5 million in loans from Pacific Western for working capital purposes under an agreement dated Aug. 22, 2014. Heat’s $2.7 million payment terminated the loan agreement.

The company reported response and survival results in the ongoing Phase 1 study evaluating Heat Biologic’s drug in combination with an already approved drug called Opdivo from Bristol-Myers Squibb for the treatment of non-small cell lung cancer.

Heat Biologics is focused on the field of cancer immunotherapy. The company’s cancer vaccine is called ImPACT, short for Immune Pan-Antigen Cytotoxic Therapy. ImPACT is in Phase 2 in the most common type of lung cancer and bladder cancer. The vaccine works by injecting genetically modified cells into a patient to elicit a powerful immune response against the disease target, the company says.

Four recent stories on Heat Biologics can be found on N.C. Business News Wire’s website.

Founded in 2008, the company reported earnings per share of negative $1.53 based on the past 12 months. Its share price has a 52-week range of 40 cents to $4.71 per share. Heat’s market capitalization stands at $23.22 million.

The form, dated Dec. 8 and filed on Dec. 9 at 4 p.m. EST, can be found here.